InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.84
(
-0.09%
)
Bitcoin
59,952.52
(
-0.35%
)
Post# of 252477
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: bladerunner1717 post# 85052

Wednesday, 10/14/2009 2:08:35 PM

Wednesday, October 14, 2009 2:08:35 PM

Post# of 252477
>Fusilev

This is a quite misguided article. The FDA does not consider the eventual cost of the drug in making its decisions. The cost isssues emerge only when payors decide whether or not to cover the drug.

I did some research on Fusilev last year. For some reason this version of the generic has good sales in Europe, but its practical (rather than theoretical) advantages over the generic seemed quite unclear to me.

Note SPPI must have gotten some temporary sales boost because of the previous shortage of the generic leucovorin:

http://chocgpo.files.wordpress.com/2009/01/leucovorinshortage.pdf

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up